Study Title

A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease

Study Details

Description:

177Lu PSMA 617 is a new type of therapy which is designed to deliver high doses of radiation directly to prostate cancer sites in the body. The purpose of this study is to find out whether 177Lu PSMA 617can slow the growth of prostate cancer compared to standard chemotherapy treatment

Sponsor:

Canadian Cancer Trials Group

Contacts:

Wendy Parulekar

wparulekar@ctg.queensu.ca

613-533-6430

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468